Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Trinity Biotech (TRIB) over the last 17 years, with Q2 2025 value amounting to $149.2 million.

  • Trinity Biotech's Total Liabilities rose 2053.57% to $149.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $149.2 million, marking a year-over-year increase of 2053.57%. This contributed to the annual value of $138.5 million for FY2024, which is 6606.42% up from last year.
  • Latest data reveals that Trinity Biotech reported Total Liabilities of $149.2 million as of Q2 2025, which was up 2053.57% from $138.5 million recorded in Q4 2024.
  • In the past 5 years, Trinity Biotech's Total Liabilities ranged from a high of $149.2 million in Q2 2025 and a low of $81.1 million during Q3 2023
  • Its 5-year average for Total Liabilities is $110.9 million, with a median of $113.2 million in 2024.
  • Per our database at Business Quant, Trinity Biotech's Total Liabilities plummeted by 2707.08% in 2022 and then skyrocketed by 6606.42% in 2024.
  • Over the past 5 years, Trinity Biotech's Total Liabilities (Quarter) stood at $119.2 million in 2021, then decreased by 20.92% to $94.3 million in 2022, then dropped by 11.56% to $83.4 million in 2023, then skyrocketed by 66.06% to $138.5 million in 2024, then increased by 7.73% to $149.2 million in 2025.
  • Its last three reported values are $149.2 million in Q2 2025, $138.5 million for Q4 2024, and $123.8 million during Q3 2024.